We have committed to end the practice of making payments to healthcare professionals (HCPs) to speak on our behalf about our medicines or vaccines to audiences who can prescribe or who can influence prescribing.
In the intervening period, we will continue to disclose any payments we do make to HCPs for speaking on our behalf about products or disease areas and for attending conferences. We are committed to publishing all other payments we make to HCPs. We already do so in several countries in line with locally agreed government or industry association standards.
We are also ending the practice of providing direct financial support for individual HCPs to attend medical conferences. In place of this, we have provided a framework for sponsorship of healthcare professionals to conferences via a 3rd party framework. GSK shall not be involved in the selection of individual HCPs to the conferences. And selected HCPs who receive sponsorship support via the third party shall remain anonymous to GSK
We will continue to support and work towards transparency in other countries as industry associations or governments establish specific guidelines for disclosure - for example, through the European Federation of Pharmaceutical Industry Association (EFPIA) code on payments.
We also continue to work towards publishing global figures at an aggregate level for the payments to HCPs, for activities such as advisory services and clinical research.